Share This Article:

Study of the Peripheral Blood CD44 Expression in the Patients with Non-Small Cell Lung Cancer

Abstract Full-Text HTML Download Download as PDF (Size:128KB) PP. 654-658
DOI: 10.4236/jct.2011.25087    4,408 Downloads   6,742 Views  

ABSTRACT

Previous study has demonstrated that the peripheral blood CD44 expression level is related with the clinical stage and lymph node metastasis of lung cancer. The present comment was to investigate the relationship between the peripheral blood CD44 expression level and clinic pathological change in 50 patients with non-small cell lung cancer (NSCLC) by flow cytometry method. The results showed that 1) the peripheral blood CD44 expression level in the NSCLC group was higher than that in the benign group (467 ± 15) or the normal group (448 ± 15); 2) operation decreased the peripheral blood CD44 expression level in the NSCLC group (533 ± 10 vs. 324 ± 11); 3) it also showed same results in NSCLC patients with and without lymph node metastasis (559 ± 12 vs. 477 ± 15) or before and after chemotherapy (550 ± 13 vs. 372 ± 10); 4) there were significant differences in the peripheral blood CD44 expression level in non-small cell lung cancer patients of the clinical stage I, II, III and IV (474 ± 14, 526 ± 12, 528 ± 16 and 599 ± 20); And the peripheral blood CD44 expression level was not associated with the clinical pathology parameter including the patient age, gender and tumor size. The data suggested that the peripheral blood CD44 expression level was related with the NSCLC progress, lymphatic metastasis and clinical treatment, and the peripheral blood CD44 expression level as the clinical regular examination should evaluate the progress, lymphatic metastasis and clinical treatment for the patients with NSCLC.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

D. Jiang, J. Yang, H. Yuan, Y. Wu, P. Qiu, G. Lu and Q. Chen, "Study of the Peripheral Blood CD44 Expression in the Patients with Non-Small Cell Lung Cancer," Journal of Cancer Therapy, Vol. 2 No. 5, 2011, pp. 654-658. doi: 10.4236/jct.2011.25087.

References

[1] S. M. Albelda, “Role of Integrins and Other Cell Adhesion Molecules in Tumor Progression and Metastasis,” Laboratory Investigation, Vol. 68, No. 1, 1993, pp. 4-17.
[2] N. Takigawa, Y. Segawa, K. Manadai, I. Takata and N. Fujimoto, “Serum CD44 Levels in Patients with Non-Small Cell Lung Cancer and Their Relationship with Clinicophathological Features,” Lung Cancer, Vol. 18, No. 2, 1997, pp. 147-157. doi:10.1016/S0169-5002(97)00060-3
[3] H. A. Kargi, M. F. Kuyucuoglu, M. Alakavuklar, O. Akpinar and S. Erk, “CD44 Expression in Metastatic and Non-Metastatic Non-Small Cell Lung Cancers,” Cancer Letters, Vol. 119, No. 1, 1997, pp. 27-30. doi:10.1016/S0304-3835(97)00254-1
[4] T. Miyoshi, K. Knodo, N. Hino, T. Uyama and Y. Monden, “The Expression of the CD44 Variant Exon 6 Is Associated with Lymph Node Metastatis in Non-Small Cell Lung Cancer,” Clinic Cancer Research, Vol. 3, 1997, pp. 1289-1297.
[5] C. F. Mountain, “A New International Staging System for Lung Cancer,” Chest, Vol. 89, No. 4, 1986, pp. 5225-5228.
[6] X. M. Sun and G. P. Yi, “The Establishment of Researching Adhesive Molecules in Solid Tumors by Flow Cytometric Method,” Chinese Journal of Medical Laboratory Sciences, Vol. 20, 1997, pp. 9-11.
[7] M. B. Penno, J. T. August, S. B. Baylin, M. Mabry, R. L. Linnoila, V. S. Lee, D. Croteau, X. L. Yang and C. Rosada, “Expression of CD44 in Human Lung Tumors,” Cancer Research, Vol. 54, 1994, pp. 1381-1387.
[8] J. Lesley, R. Hyman and P. W. Kincade, “CD44 and Its Interactions with the Extracellular Matrix,” Advances in Immunology, Vol. 54, 1993, pp. 271-335. doi:10.1016/S0065-2776(08)60537-4
[9] D. Situ, H. Long, P. Lin, Z. Zhu, J. Wang, X. Zhang, Z. Xie and T. Rong, “Expression and Prognostic Relevance of CD44v6 in Stage I Non-Small Cell Lung Carcinoma,” Journal of Cancer Research and Clinic Oncology, Vol. 136, No. 8, 2010, pp. 1213-1219. doi:10.1007/s00432-010-0771-5
[10] A. S. Adhikari, N. Agarwal and T. Iwakuma, “Metastatic Potential of Tumor-Initiating Cells in Solid Tumors,” Front Biosciences, Vol. 16, 2011, pp. 1927-1938. doi:10.2741/3831
[11] M. Hofmann, W. Rudy, M. Zoller, C. Tolg, H. Ponta, P. Herrlich and U. Gunthert, “CD44 Splice Variants Confer Metastatic Behavior in Rats: Homologous Sequences Are Expressed in Human Tumor Cell Lines,” Cancer Research, Vol. 51, 1991, pp. 5292-5297.
[12] P. Klingbeil, R. Marhaba, T. Jung, R. Kirmse, T. Ludwig and M. Zoller, “CD44 Variant Isoforms Promote Metastasis Formation by a Tumor Cell-Matrix Cross-Talk That Supports Adhesion and Apoptosis Resistance,” Molecular Cancer Research, Vol. 7, 2009, pp. 168-179. doi:10.1158/1541-7786.MCR-08-0207
[13] U. Valentiner, F. U. Valentiner and U. Schumacher, “Expression of CD44 Is Associated with a Metastatic Pattern of Human Neuroblastoma Cells in a SCID Mouse Xenograft Model,” Tumour Biolology, Vol. 29, No. 3, 2008, pp. 152-160. doi:10.1159/000143401
[14] S. Riethdorf, H. Wikman and K. Pantel, “Review: Biological Relevance of Disseminated Tumor Cells in Cancer Patients,” International Journal of Cancer, Vol. 123, No. 9, 2008, pp. 1991-2006. doi:10.1002/ijc.23825

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.